Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years

Epilepsia

Volumn 55, Issue 4, 2014, Pages 558-567

  Conry, Joan A ^a   Ng, Yu Tze ^b   Kernitsky, Lydia ^c   Mitchell, Wendy G ^d   Veidemanis, Rima ^e   Drummond, Rebecca ^e   Isojarvi, Jouko ^e   Lee, Deborah ^e   Paolicchi, Juliann M ^f  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e LUNDBECK RESEARCH USA   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drug; Benzodiazepines; Clinical trials; Drop seizures; Epilepsy

Indexed keywords

CLOBAZAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; ASPIRATION PNEUMONIA; CHILD; CONVULSION; DEHYDRATION; DISEASE ASSOCIATION; DROP SEIZURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY MONITORING; EPILEPTIC STATE; FEMALE; HUMAN; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEIZURE; TREATMENT DURATION; UNITED STATES; URINARY TRACT INFECTION; VITAL SIGN; CLINICAL TRIAL; CONTROLLED STUDY; INTELLECTUAL DISABILITY; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SEIZURES; SPASMS, INFANTILE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTELLECTUAL DISABILITY; LENNOX GASTAUT SYNDROME; MALE; MIDDLE AGED; SEIZURES; SPASMS, INFANTILE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899485705     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12561     Document Type: Article

References (19)

1. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009; 8: 82-93.
2. Camfield PR,. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia 2011; 52 (Suppl. 5): 3-9.
3. Chevrie JJ, Aicardi J,. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases. Epilepsia 1972; 13: 259-271.
4. Berg AT, Shinnar S, Testa FM, et al. Mortality in childhood-onset epilepsy. Arch Pediatr Adolesc Med 2004; 158: 1147-1152.
5. Crumrine PK,. Lennox-Gastaut syndrome. J Child Neurol 2002; 17 (Suppl. 1): S70-S75.
6. Trevathan E,. Infantile spasms and Lennox-Gastaut syndrome. J Child Neurol 2002; 17 (Suppl. 2): 2S9-2S22.
7. Arzimanoglou A, Resnick T,. All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome... but many do. Epileptic Disord 2011; 13 (Suppl. 1): S3-S13.
8. Montouris GD,. Rational approach to treatment options for Lennox-Gastaut syndrome. Epilepsia 2011; 52 (Suppl. 5): 10-20.
9. Ng YT, Collins SD,. Clobazam. Neurotherapeutics 2007; 4: 138-144.
10. A Receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 2012; 26: 229-244.
11. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50: 1158-1166.
12. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77: 1473-1481.
13. Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 2012; 25: 687-694.
14. Glauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia 2000; 41 (Suppl. 1): S86-S90.
15. Dodson WE,. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 (Suppl. 7): S18-S24.
16. Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010; 122: 202-208.
17. Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118: 69-86.
18. Lee EH, Yum MS, Choi HW, et al. Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center. Clin Neuropharmacol 2013; 36: 4-7.
19. Wheless JW, Vazquez B,. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010; 10: 1-6.